1
|
Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity. Circulation 2013. [DOI: 10.1161/circulationaha.112.091215] [Citation(s) in RCA: 178] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Cardiac consequences of obesity include inflammation, hypertrophy, and compromised energy metabolism. Glucagon-like peptide-1 is an incretin hormone capable of cytoprotective actions that reduces inflammation and endoplasmic reticulum stress in other tissues. Here we examine the cardiac effects of the glucagon-like peptide-1 analog liraglutide in a model of obesity, independent of changes in body weight.
Methods and Results—
C57Bl6 mice were placed on a 45% high-fat diet (HFD) or a regular chow diet. Mice on HFD developed 46±2% and 60±2% greater body weight relative to regular chow diet–fed mice at 16 and 32 weeks, respectively (both
P
<0.0001), manifesting impaired glucose tolerance, insulin resistance, and cardiac ceramide accumulation by 16 weeks. One-week treatment with liraglutide (30 µg/kg twice daily) did not reduce body weight, but reversed insulin resistance, cardiac tumor necrosis factor-α expression, nuclear factor kappa B translocation, obesity-induced perturbations in cardiac endothelial nitric oxide synthase, connexin-43, and markers of hypertrophy and fibrosis, in comparison with placebo-treated HFD controls. Liraglutide improved the cardiac endoplasmic reticulum stress response and also improved cardiac function in animals on HFD by an AMP-activated protein kinase–dependent mechanism. Supporting a direct mechanism of action, liraglutide (100 nmol/L) prevented palmitate-induced lipotoxicity in isolated mouse cardiomyocytes and primary human coronary smooth muscle cells and prevented adhesion of human monocytes to tumor necrosis factor-α–activated human endothelial cells in vitro.
Conclusions—
Weight-neutral treatment with a glucagon-like peptide-1 analog activates several cardioprotective pathways, prevents HFD-induced insulin resistance and inflammation, reduces monocyte vascular adhesion, and improves cardiac function in vivo by activating AMP-activated protein kinase. These data support a role for glucagon-like peptide-1 analogs in limiting the cardiovascular risks of obesity.
Collapse
Affiliation(s)
- Mohammad Hossein Noyan-Ashraf
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Eric Akihiko Shikatani
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Irmgard Schuiki
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Ilya Mukovozov
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Jun Wu
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Ren-Ke Li
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Allen Volchuk
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Lisa Annette Robinson
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Filio Billia
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Daniel J. Drucker
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| | - Mansoor Husain
- From the Toronto General Research Institute, Toronto, Canada (M.H.N.-A., E.A.S., I.S., J.W., R.-K.L., A.V., F.B., M.H.); Hospital for Sick Children, Toronto, Canada (I.M., L.A.R.); Samuel Lunenfeld Research Institute, Toronto Canada (D.J.D.); Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Canada (D.J.D., M.H.)
| |
Collapse
|